WHO Pharmaceuticals Newsletter 2002, No. 03
(2002; 22 pages) Ver el documento en el formato PDF
Índice de contenido
Cerrar esta carpetaREGULATORY MATTERS
Ver el documentoARISTOLOCHIC ACID - Warnings on more products containing Aristolochic acid
Ver el documentoARTHRIN, OSPORO, POENA AND OTHERS - Presence of undeclared prescription drugs poses health threat
Ver el documentoASPIRIN - Restrictions on use in children extended to teenagers
Ver el documentoBACLOFEN - Life threatening sequelae and/or death with abrupt withdrawal of intrathecal injections
Ver el documentoBEJAI BOWYANTAN - Risk of toxicity in children due to presence of Borneol
Ver el documentoCELECOXIB - CLASS findings added to product label
Ver el documentoEPOETIN-ALFA - Important safety update
Ver el documentoGLITAZONES - strengthens labelling for cardiovascular risks
Ver el documentoHORMONE REPLACEMENT THERAPY (HRT) - Product information updated
Ver el documentoIRINOTECAN - Labelling updated
Ver el documentoKAVA-KAVA - More withdrawals due to hepatotoxic risks
Ver el documentoMELOXICAM - Additional information in package insert
Ver el documentoMISOPROSTOL - Major labelling changes
Ver el documentoNIMESULIDE - Temporary suspension pending further evaluation
Ver el documentoOLANZAPINE - Risk of hyperglycaemia
Ver el documentoPOOLED PLASMA (HUMAN) SOLVENT DETERGENT TREATED - Boxed warning to indicate new contraindication
Ver el documentoPROPOFOL - Contraindication section modified
Ver el documentoROFECOXIB - Reports of gastrointestinal/cardio vascular toxicity; labelling updated
Ver el documentoSIROLIMUS - Correction to drug safety information
Ver el documentoSLIM 10 - Withdrawn due to presence of adulterants
Ver el documentoTAMOXIFEN - Boxed warning added to product label
Ver el documentoTETRABAMATE - Withdrawal due to reports of hepatotoxicity
Ver el documentoVALPROATE - Labelling strengthened
Ver el documentoZONISAMIDE - Prescribing information updated
Abrir esta carpeta y ver su contenidoSAFETY OF MEDICINES
Abrir esta carpeta y ver su contenidoDRUGS OF CURRENT INTEREST
Abrir esta carpeta y ver su contenidoFEATURE
Ver el documentoEVENTS & ANNOUNCEMENTS
 

ARISTOLOCHIC ACID - Warnings on more products containing Aristolochic acid

Canada.

Health Canada is advising Canadians not to consume Longdan or Lung Tan Xi Gan products since they may contain herbs with aristolochic acid. Aristolochic acid is considered carcinogenic and has been shown to cause mutations in human cells and end-stage kidney failure. Health Canada is working with the manufacturers, distributors and importers to recall these products in Canada. A customs alert has also been issued, to prevent the importation of these products into Canada. Health Canada first issued a warning on aristolochic acid in November 1999 that this ingredient posed a Class I Health Hazard with a potential to cause serious health effects or death.

Readers are referred to previous issues of the WHO Pharmaceuticals Newsletter (Nos. 2&3, 2001; Issue No. 1, 2002; Issue No. 2, 2002) for earlier reports on safety and regulatory measures on aristolochic acid-containing products in other countries.

Reference:

Health Canada Warnings/Advisories, 16 May 2002. Available from URL: http://www.hc-sc.gc.ca

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 3 mayo 2013